234 related articles for article (PubMed ID: 23997016)
1. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.
Anderson PM; Meyers P; Kleinerman E; Venkatakrishnan K; Hughes DP; Herzog C; Huh W; Sutphin R; Vyas YM; Shen V; Warwick A; Yeager N; Oliva C; Wang B; Liu Y; Chou A
Pediatr Blood Cancer; 2014 Feb; 61(2):238-44. PubMed ID: 23997016
[TBL] [Abstract][Full Text] [Related]
2. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
[TBL] [Abstract][Full Text] [Related]
3. The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis.
Kokkali S; Kotsantis I; Magou E; Sophia T; Kormas T; Diakoumis G; Spathas N; Psyrri A; Ardavanis A
Invest New Drugs; 2022 Jun; 40(3):668-675. PubMed ID: 35312944
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.
Venkatakrishnan K; Kramer WG; Synold TW; Goodman DB; Sides E; Oliva C
Eur J Clin Pharmacol; 2012 Oct; 68(10):1347-55. PubMed ID: 22460239
[TBL] [Abstract][Full Text] [Related]
5. Mifamurtide: a review of its use in the treatment of osteosarcoma.
Frampton JE
Paediatr Drugs; 2010 Jun; 12(3):141-53. PubMed ID: 20481644
[TBL] [Abstract][Full Text] [Related]
6. Mifamurtide in osteosarcoma--a practical review.
Anderson PM; Tomaras M; McConnell K
Drugs Today (Barc); 2010 May; 46(5):327-37. PubMed ID: 20517534
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review.
Jimmy R; Stern C; Lisy K; White S
JBI Database System Rev Implement Rep; 2017 Aug; 15(8):2113-2152. PubMed ID: 28800058
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
[TBL] [Abstract][Full Text] [Related]
9. Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma.
Brosa M; García del Muro X; Mora J; Villacampa A; Pozo-Rubio T; Cubells L; Montoto C
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):331-40. PubMed ID: 25354299
[TBL] [Abstract][Full Text] [Related]
10. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
Meyers PA; Chou AJ
Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
[TBL] [Abstract][Full Text] [Related]
11. The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma.
Tacyildiz N; Incesoy Ozdemir S; Unal E; Berber M; Dincaslan H; Yavuz G
J Pediatr Hematol Oncol; 2018 Aug; 40(6):e373-e376. PubMed ID: 29889801
[TBL] [Abstract][Full Text] [Related]
12. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.
Meyers PA
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1035-49. PubMed ID: 19671023
[TBL] [Abstract][Full Text] [Related]
13. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
Ando K; Mori K; Corradini N; Redini F; Heymann D
Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
[TBL] [Abstract][Full Text] [Related]
14. Liposomal MTP-PE.
Gano JB; Kleinerman ES
J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
[No Abstract] [Full Text] [Related]
15. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract][Full Text] [Related]
16. Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).
Barnes DJ; Dutton P; Bruland Ø; Gelderblom H; Faleti A; Bühnemann C; van Maldegem A; Johnson H; Poulton L; Love S; Tiemeier G; van Beelen E; Herbschleb K; Haddon C; Billingham L; Bradley K; Ferrari S; Palmerini E; Picci P; Dirksen U; Strauss SJ; Hogendoorn PCW; Buddingh E; Blay JY; Cleton-Jansen AM; Hassan AB
BMC Cancer; 2022 Jun; 22(1):629. PubMed ID: 35672690
[TBL] [Abstract][Full Text] [Related]
17. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
18. Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience.
Taçyıldız N; Unal E; Dinçaslan H; Çakmak HM; Köse K; Tanyıldız G; Kartal Ö
Asian Pac J Cancer Prev; 2020 Mar; 21(3):715-720. PubMed ID: 32212798
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.
Venkatakrishnan K; Liu Y; Noe D; Mertz J; Bargfrede M; Marbury T; Farbakhsh K; Oliva C; Milton A
Br J Clin Pharmacol; 2014 Jun; 77(6):998-1010. PubMed ID: 24134216
[TBL] [Abstract][Full Text] [Related]
20. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine.
Drugs R D; 2008; 9(2):131-5. PubMed ID: 18298131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]